Loading…
Loading…
INNO (Harbor Disruptive Innovation ETF) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
INNO does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See exactly how INNO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for INNO and 80,000+ other tickers.
The Harbor Disruptive Innovation ETF typically allocates its portfolio to common stocks of companies believed to offer significant growth potential through transformative breakthroughs. The adviser defines "disruptive innovation" as the introduction of novel products, services, technologies, or other advancements capable of fundamentally redefining or displacing existing industries and business models over time. While the fund's holdings are predominantly U.S.-based companies, it has the flexibility to invest up to 25% of its assets in international securities, including those from emerging market economies.
HERZLIYA, Israel and CALGARY, AB, Feb. 27, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA's Center for Veterinary Medicine (CVM) has granted the Company a sponsor fee waiver for its LPT-CBD (Liposome Platform Technology-Cannabidiol) product for the third consecutive year. The FDA's Center for Veterinary Medicine (CVM) assesses annual fees for animal drug applications.
HERZLIYA, Israel and CALGARY, AB, Feb. 9, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication of a research article titled "Efficacy, pharmacokinetics and safety of liposomal synthetic cannabidiol injected subcutaneously in dogs: a randomized, blinded, placebo-controlled, crossover clinical trial" in the esteemed peer reviewed journal Frontiers in veterinary science (https://doi.org/10.3389/fvets.2025.1746266) (1). Key findings include: Significant improvement in behavior/function reported by owners (p = 0.0217), with 100% of dogs showing improved function after LPT-CBD vs 25% after placebo.
/PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on
Brookshire, Texas, Dec. 13, 2024 (GLOBE NEWSWIRE) -- INNO HOLDINGS INC. (“INNO” or the “Company”) (NASDAQ : INHD) is a trade-focused building technology company dedicated to revolutionizing the construction industry with its proprietary cold-formed steel framing technology, artificial intelligence (“AI”)-driven design, and advanced automation to deliver innovative and efficient building solutions. In addition to its existing business, the Company is now developing a new venture in electronic products trading while expanding its sales and distribution network across Asia. INNO consistently seeks innovative ways to enhance services and technologies and delivers high-quality products to its clients.
As recent advancements in are AI top of mind, many investors are looking to invest in disruptive innovation ETFs. There are many disruptive innovation ETFs available to investors.